



Amelia Feulner Baur, PhD

Founding Partner

Personalized representation from a leader in precision medicine and biologics patent law

Amelia Feulner Baur's practice covers a broad spectrum of intellectual property issues, including patent preparation and prosecution, coordination of worldwide patent strategies, appeals to the Patent Trial and Appeal Board (PTAB) of the US Patent and Trademark Office and the Court of Appeals for the Federal Circuit (CAFC). Amelia has been recognized as an IP Star by Managing Intellectual Property.



She has extensive experience working with clients to develop effective patent strategies to meet business goals. This includes landscape analyses, due diligence investigations, and providing patentability, freedom-to-operate, infringement, and validity opinions. In addition, Amelia has led clients through inter partes review (IPR), reexaminations, interferences, and the settlement of patent disputes. She has worked with biotech startups, research foundations, and larger, established pharmaceutical companies.

Amelia earned her PhD degree in molecular microbiology, where she gained extensive hands-on experience in the fields of microbiology, immunology, biochemistry, molecular biology, and infectious disease. She has substantial legal experience in many biotechnology and pharmaceutical practice areas including antibodies and antibody variants, diagnostic and detection methods, protein purification, vaccine technology, fusion proteins, gene cloning and expression, and gene and protein mutations.

Prior to founding McNeill Baur PLLC, Amelia spent more than a decade at two large IP firms: Finnegan, Henderson, Farabow, Garrett & Dunner, LLP and Nixon Peabody, LLP.

She is married to Dr. Joseph Baur, Associate Professor in the Department of Physiology and Institute for Diabetes, Obesity and Metabolism, at Perelman School of Medicine at the University of Pennsylvania.

Recognition

2016 and 2017 IP Star, Managing Intellectual Property.

2016 and 2017 Rising Star, SuperLawyers.

Leadership Roles

American Bar Association (ABA), Chair, Section of Intellectual Property Law: Patents in the Chemical and Life Sciences (beginning Sept 2017); Vice-Chair (2015-2017)

610.667.2014
amelia.baur@mcneillbaur.com
McNeill Baur PLLC
Two Bala Plaza
Suite 300, #507
Bala Cynwyd, PA 19004

Admissions

Pennsylvania
Massachusetts
US Patent and Trademark Office
US Court of Appeals, Federal Circuit (CAFC)
US Supreme Court
US Court of Appeals, Veterans Claims (CAVC)

Education

Suffolk University Law School
JD, 2008

The University of Texas
Southwestern Medical Center at Dallas
PhD, Molecular Microbiology, 2003

Russell Sage College
BA, Biology, 1998, magna cum laude,
highest honors



Amelia Feulner Baur, PhD

Selected Publications

“Navigating the Limitations on Discovery in AIA Post-Grant Proceedings,” *Buffalo Intellectual Property Law Journal*, December 3, 2015 (coauthor).

“US Supreme Court Provides New Hurdles for Personalized Medicine in *Limelight Networks v. Akamai Technologies*,” *Bloomberg BNA, World Intellectual Property Report*, September 2014.

“Comments of the American Bar Association Section of Intellectual Property in Response to the USPTO’s Guidance for Determining Subject Matter Eligibility of Claims Reciting or Involving Laws of Nature, Natural Phenomena & Natural Products,” July 30, 2014 (coauthor).

“Ask The Expert: Are Diagnostic Patents Dead?,” *Clinical Laboratory News* 40(7):44 (2014).

“Personalized Medicine Patents at Risk: Tips for Battling Prometheus and Myriad to Obtain Claims to Diagnostics,” *CIPA Journal*, March 2013 (coauthor).

“Patenting Personalized Medicine,” *The Journal of Biolaw and Business*, 2006 (coauthor).

Selected Speaking Engagements

The Knowledge Group Webinar, *USPTO’s Subject Matter Eligibility: The Dos and Don’ts in 2016 and Beyond*, November 15, 2016.”

The Institute of Professional Representatives before the European Patent Office (epi), *Recent developments, key case law and current landscape of patent eligibility*, November 20, 2015, Eindhoven, The Netherlands.

AIPLA Biotech Patent Law Road Show, *Divided Infringement and Claim Drafting in a Post-Myriad, Mayo, Akamai, Ariosa World*, September 10, 2015, Boston, MA.

Strafford Publications Webinar, Patent Subject Matter Eligibility: Navigating the New “Myriad” Guidelines, April 16, 2014, and May 15, 2014.

BPLA, Moderator, Hot Topics in European and US Patent Law: Comparing, Contrasting, and Harmonizing Strategies with Focus on Post-Grant Proceedings, Unitary Patent System, Biosimilars, and Patent Misuse, April 1, 2014.